General paediatric at Karolinska University Hospital, Huddinge
Postdoc at Karolinska Institute (KBH)
It is well known that sex steroids particularly estrogens are important for longitudinal bone growth during puberty. High dose estrogen therapy has been used to reduce final height has been shown to be effective but associated with severe side effects. In contrast, inhibition of estrogen production using aromatase inhibitors to improve final height has been shown to inhibit bone turnover which affects bone architecture and may results increase risk of vertebrae fracture. Selective estrogen receptor modulators (SERMs), which display estrogenic and or anti-estrogenic effects, have the ability to bind to estrogen receptors (ER)s with different affinities and subsequently recruit co-modulators in a tissue specific manner. So, we hypothesized that SERMs might be an effective tool to modulate longitudinal bone growth. We have shown previously that tamoxifen (the first generation of SERM) at a clinically relevant dose causes persistent retardation of longitudinal bone growth in rats. However it was resulted with weaker bones which theoretically could increase the risk of fracture. Recently we showed that Resveratrol, a phytoSERM, improved longitudinal bone growth in rabbits.
More investigations in this area need to be done aiming to modulate longitudinal bone growth in extreme short or tall adolescents with the least possible side effects.
Education: M.D. (1996), PhD (2010)